361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER

Autor:	C. Wu, J.H. Strickler, A. Cercek, S. Siena, T. André, K. Ng, E. Van Cutsem, A.S. Paulson, J. Hubbard, A. Coveler, C. Fountzilas, A. Kardosh, P.M. Kasi, H.J. Lenz, K.K. Ciombor, M.E. Elez Fernandez, L-I. Hsu, M. Stecher, K. Zhao, T. Bekaii-Saab
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S700-S701
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2022.07.499
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::065b524d64325cac958f9ccff595644b https://doi.org/10.1016/j.annonc.2022.07.499 Zobrazit plný text záznamu